Mirati Therapeutics, Inc. (MRTX)

Market Cap	5.27B
Revenue (ttm)	11.80M
Net Income (ttm)	-738.01M
Shares Out	56.22M
EPS (ttm)	-11.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	815,083
Open	96.21
Previous Close	96.25
Day's Range	88.69 - 96.47
52-Week Range	32.96 - 154.17
Beta	0.83
Analysts	Buy
Price Target	118.00 (+28.3%)
Earnings Date	Nov 8, 2022

About MRTX

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclini...

• Industry: Biotechnology
• IPO Date: Jun 29, 2004
• CEO: Charles Baum
• Employees: 413
• Stock Exchange: NASDAQ
• Ticker Symbol: MRTX

Financial Performance

In 2021, MRTX's revenue was $72.09 million, an increase of 438.08% compared to the previous year's $13.40 million. Losses were -$581.78 million, 62.5% more than in 2020.

Analyst Forecast

According to 24 analysts, the average rating for MRTX stock is "Buy." The 12-month stock price forecast is 118, which is an increase of 28.33% from the latest price.

Price Target

$118

(28.33% upside)

Analyst Consensus: Buy